Autologous Hematopoietic Stem Cell Transplantation Indication to Patients over 65 Years Old as Treatment of Choice for Multiple Myeloma

Cristina Vogel; Bruna Franco Massa; Nelson Hamerschlak; Cinthya Correa Silva; Fabio R. Kerbauy; Danielle Ovigli Lopes; Beatriz Araujo da Silva

首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Autologous Hematopoietic Stem Cell Transplantation Indication to Patients over 65 Years Old as Treatment of Choice for Multiple Myeloma

【24h】

Autologous Hematopoietic Stem Cell Transplantation Indication to Patients over 65 Years Old as Treatment of Choice for Multiple Myeloma

机译：自体造血干细胞移植指示65岁以上患者的患者，以治疗多发性骨髓瘤的选择

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2018年第3期|共2页
作者
Cristina Vogel; Bruna Franco Massa; Nelson Hamerschlak; Cinthya Correa Silva; Fabio R. Kerbauy; Danielle Ovigli Lopes; Beatriz Araujo da Silva;
展开▼
作者单位

BMT Hospital Israelita Albert Einstein;

Albert Einstein Hospital;

BMT Hospital Israelita Albert Einstein;

BMT Hospital Israelita Albert Einstein;

Hematology and Bone Marrow Transplantation Dept UNIFESP (Universidade Federal de Sao Paulo);

Albert Einstein Hospital;

Albert Einstein Hospital;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Autologous Hematopoietic Stem Cell Transplantation Indication to Patients over 65 Years Old as Treatment of Choice for Multiple Myeloma [J] . Cristina Vogel, Bruna Franco Massa, Nelson Hamerschlak, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：自体造血干细胞移植指示65岁以上患者的患者，以治疗多发性骨髓瘤的选择
2. Autologous Hematopoietic Stem Cell Transplantation Indication to Patients over 65 Years Old as Treatment of Choice for Multiple Myeloma [J] . Cristina Vogel, Bruna Franco Massa, Nelson Hamerschlak, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：自体造血干细胞移植指示65岁以上患者的患者，以治疗多发性骨髓瘤的选择
3. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis [J] . Minoia C., Pisapia G., Palazzo G., Bone marrow transplantation . 2015,第11期

机译：新药与自体造血干细胞移植对65岁或65岁以上多发性骨髓瘤患者的影响：回顾性单一机构分析
4. HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PATIENTS WITH PRIMARY SYSTEMIC AMYLOIDOSIS (AL): AN ABMTR STUDY [C] . DH Vesole, W Perez, D Reece, International Symposium on Amyloidosis . 2005

机译：具有自体造血干细胞移植（HSCT）的高剂量治疗用于初级全身淀粉样蛋白症（AL）的患者：ABMTR研究
5. Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation [D] . Miller, Kevin Charles. 2020

机译：改善多发性骨髓瘤结果的策略：靶向MEK，HDAC和BCL-2的临床前治疗方法以及优化自体造血细胞移植
6. Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials [O] . Mohamed A Kharfan-Dabaja, Mehdi Hamadani, Tea Reljic, 2013

机译：自体串联与自体串联同种异体造血细胞移植在新诊断多发性骨髓瘤患者中的比较疗效：随机对照试验的系统评价和荟萃分析
7. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis [O] . C Minoia, G Pisapia, G Palazzo, 2015

机译：新型剂对65岁或以上的多发性骨髓瘤患者的自体造血干细胞移植的影响：回顾性单一制度分析

Autologous Hematopoietic Stem Cell Transplantation Indication to Patients over 65 Years Old as Treatment of Choice for Multiple Myeloma

著录项

相似文献

相关主题

期刊订阅